关于我们

Founded in 2018, China Immunotech (Beijing)Biotechnology Co., LTD is dedicated to biopharmaceutics research and development. The founder and leading scientist, Dr. Xin Lin, was from MD Anderson Cancer Center of the United States, and now is a full-time tenured chair professor of Tsinghua University in Beijing,China. The core technology team is composed of postdoctoral fellows and PhD researchers from top universities and institutes, with high-level expertise in biology, immunology and biomedical research.

查看更多

News

  • Company News

    On October 17, 2018.The company's founder professor Xin Lin, on behalf of the school of medicine of Tsinghua University, signed a cooperation agreement with Peihua Lu, the director of Daopei Lu Research Institute, to establish a joint research center for blood tumor, which can better combine "basic research" and "clinical practice", and develop scientific research and benefit patients based on clinical needs.

    【查看更多】

  • Company News

    On September 25, 2018.We launched a clinal trial on evaluating the therapeutical efficacy and safety of using EBV-TCR-T cell to treat refractory nasopharyngeal carcinoma. The trail has already gained ethical approval from the Fujian Oncology Hospital (clinical trial: NCT03648697).

    【查看更多】

  • Company News

    On September 18, 2018.The company completed capital financing of 30 million yuan.

    【查看更多】